Anti-metastasis therapy for Lung cancer: Campothecin (CPT) inhibits lung cancer progression via down regulation of the SRC/Ras/ERK pathway, 26/August/2014, 06.16 am

Anti-metastasis therapy for Lung cancer: Campothecin (CPT) inhibits lung cancer progression via down regulation of the SRC/Ras/ERK pathway, 26/August/2014, 06.16 am

Anti-metastasis therapy for Lung cancer: Campothecin (CPT) inhibits lung cancer progression via down regulation of the SRC/Ras/ERK pathway, 26/August/2014, 06.16 am 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., Anti-metastasis therapy for Lung cancer:  Campothecin (CPT) inhibits lung cancer progression via down regulation of the SRC/Ras/ERK pathway, 26/August/2014, 06.16 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Significance: This study elucidates the mechanism by which Campothecin (CPT) inhibits metastatic lung cancer.